Japer Therapeutics Warrants
JSPRW
10 hedge funds and large institutions have $345K invested in Japer Therapeutics Warrants in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0% more funds holding
Funds holding: 10 → 10 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
3.17% less ownership
Funds ownership: 5.34% → 2.17% (-3.2%)
20% less capital invested
Capital invested by funds: $431K → $345K (-$86.4K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
Ionic Capital Management
New York
|
+$28.5K |
| 2 |
CAC
Cowen and Company
New York
|
+$18.7K |
| 3 |
Walleye Capital
New York
|
+$7.07K |
| 4 |
Morgan Stanley
New York
|
+$15 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EPM
Equitec Proprietary Markets
Chicago,
Illinois
|
-$1.74K |
JSPRW Hedge Fund Activity: Q2 2023 in Review
10 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Japer Therapeutics Warrants (JSPRW) for Q2 2023, worth a combined $345K — down 20% from $431K a quarter earlier.
Fund positioning in JSPRW was balanced in Q2 2023: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 1 trimmed.
The largest buyer was Ionic Capital Management, adding an estimated $28.5K. The largest seller was Equitec Proprietary Markets, cutting an estimated $1.74K.
- 10 institutional investors held Japer Therapeutics Warrants (JSPRW) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $345K of Japer Therapeutics Warrants stock for Q2 2023, down 20% quarter-over-quarter.
- 1 fund opened new Japer Therapeutics Warrants positions in Q2 2023 and 1 closed out, a net change of 0 holders.
- The largest Japer Therapeutics Warrants buyer in Q2 2023 was Ionic Capital Management, an estimated $28.5K added.
- The largest Japer Therapeutics Warrants seller in Q2 2023 was Equitec Proprietary Markets, an estimated $1.74K sold.
Based on aggregated 13F filings for Q2 2023.